ArticleTherapeutic advances in medical oncology2024

Cost-effectiveness analysis of durvalumab plus tremelimumab as first-line therapy in patients with unresectable hepatocellular carcinoma.

Weiting Liao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.